RAC1 and colorectal carcinoma: To further confirm the antimetastatic potential of Rac1 inhibition on 5-FU resistant CRC, we performed an intrasplenic cell injection, noting that 1A-116 treatment drastically reduced spleen tumor formation and resistant cell dissemination to the liver (Figure 6G–J).